Using Sildenafil to Improve Exercise Capacity in Mild COPD
Official title: The Effect of Oral Sildenafil on Exercise Capacity, Dyspnea and Cardiopulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)
Run by University of Alberta · NCT05061368 · Data updated 2026-11-12
This study is testing if the medication Sildenafil can help people with mild COPD exercise better and breathe easier.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | University of Alberta Academic / other |
| Locations | 1 site (Edmonton, Alberta) |
| Status | Recruiting |
| Started | March 1, 2022 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT05061368 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with mild COPD who meet specific pulmonary function criteria.
✕Probably not a fit
Patients with moderate to severe COPD or those with pre-existing cardiac conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of oral Sildenafil on exercise capacity, dyspnea, and cardiopulmonary function in patients with mild Chronic Obstructive Pulmonary Disease (COPD). The study aims to understand how pulmonary vascular dysfunction contributes to exercise intolerance in these patients. Participants will be given either Sildenafil or a placebo, and their responses will be measured through various pulmonary function tests and exercise assessments. The trial seeks to clarify the mechanisms behind exertional dyspnea in mild COPD and evaluate the potential therapeutic benefits of Sildenafil.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with mild COPD, enhancing their exercise capacity and quality of life.
How similar studies have gone: Previous studies have shown promising results using similar approaches to address pulmonary vascular dysfunction in COPD, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants will have COPD as defined as: 1. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) below the lower limit of normal 2. FEV1 \>30% of predicted (lower limit of GOLD severe COPD classification) COPD Free Controls will have: 1. No diagnosis of COPD 2. Post bronchodilator Forced Expiratory Volume in one second (FEV1) to Forced Vital Capacity (FVC) ratio (FEV1/FVC) above the lower limit of normal 3. FEV1 \>80% of predicted Exclusion Criteria: 1. Absolute contraindication to exercise testing or an orthopedic condition that may limit exercise testing. 2. Pre-existing cardiac conditions (heart failure, congenital heart defect, valvular disease) that may limit exercise testing 3. A diagnosis of pulmonary hypertension preceding COPD 4. Current phosphodiesterase type-5 inhibitor, nitrate, opioid, azole antifungal, macrolide antibiotic, protease inhibitor, alpha blocker, riociguat, mifepristone or rifamycin use. 5. Pregnancy or lactation. 6. Women of childbearing potential must be willing to use an acceptable method of contraception to avoid pregnancy throughout the study. Acceptable methods of contraception include tubal ligation, oral contraceptive, barrier methods (intra-uterine device, diaphragm, female condom, male condom). Abstinence is an acceptable form of contraception, only insofar as patients agree to use another acceptable method of birth control, preferably a barrier method, if they become sexually active. 7. Postmenopausal female participants must be amenorrheic for ≥12 months.
Where it's running
-
Clinical Physiology Laboratory
Edmonton, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Michael K Stickland, Ph.D. — University of Alberta
- Study coordinator: Desi Fuhr, MSc
- Email: fuhr@ualberta.ca
- Phone: 7804921121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Flutter therapy added to chest physiotherapy after CABG in COPD patients
This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.
-
TPB-based cadence exercise and breathing training for COPD patients
A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.
-
See how dynamic chest X-rays relate to COPD patterns and progression risk
This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.
-
Personalized mobile app warnings to reduce COPD flares
A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.
-
CLEAR model to predict when people with severe COPD can be taken off ventilatory support
This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.
-
Long-term safety of Tozorakimab in COPD patients with prior exacerbations
This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.